Keywords: Warner Chilcott, Watson Pharma, Law suit, ANDA, Lo Loestrin, Contraceptive, Actavis, Requip, GlaxoSmithKline, USA, RLS, Parkinson's disease
Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip
Article | 20 May 2012
Ireland-headquartered Warner Chilcott (Nasdaq: WCRX) has filed suit against USA-based Watson Pharmaceuticals (NYSE: WPI) on May 16, in the US District ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
